Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK's vaccine receives positive European Medicines Agency opinion
03:53am, Monday, 29'th Jul 2024
GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to exten
GSK settles another Illinois Zantac lawsuit
03:37am, Monday, 29'th Jul 2024
British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements t
Here's Why GSK (GSK) is a Strong Momentum Stock
10:51am, Friday, 26'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59
07:12am, Friday, 26'th Jul 2024
The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
12:00pm, Wednesday, 24'th Jul 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 24'th Jul 2024
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
11:21am, Monday, 22'nd Jul 2024
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
Is GSK a Top-Value Stock Right Now?
08:00am, Wednesday, 17'th Jul 2024
GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to shareholders
3 Top Cancer Treatment Stocks to Buy Now
06:30am, Wednesday, 17'th Jul 2024
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in reven
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 16'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK CEO and Fleming Initiative Chair on Fighting Drug-Resistant 'Superbugs'
07:07am, Tuesday, 16'th Jul 2024
Emma Walmsley, CEO of GSK and Ara Darzi, Executive Director of the Fleming Initiative and Imperial College's Director of the Institute of Global Health Innovation, on their efforts to combat the rise
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
06:15am, Friday, 12'th Jul 2024
Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
10:31am, Wednesday, 10'th Jul 2024
GSK plc GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development.
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
07:00am, Monday, 08'th Jul 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
Will GSK Stock Rebound To Its 2022 Highs Of $47?
09:00am, Friday, 05'th Jul 2024
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over th
